Constipation
Conditions
Keywords
Drug Therapy
Brief summary
The main aim of this study is to check the side effects from lubiprostone in adults with constipation. Participants will be treated with lubiprostone according to their clinic's standard practice.
Detailed description
This is a prospective, observational post-marketing surveillance study of lubiprostone in participants with constipation. The study will assess the safety and effectiveness of lubiprostone for its approved indication with real-world setting in South Korea. The study will enroll approximately 3000 participants. The data will be collected prospectively at the study sites will be recorded into electronic case report forms (e-CRFs). All the participants will be assigned to a single observational cohort: • All Participants The study will be conducted in South Korea. The overall duration of the study will be approximately 6 years. Data collection will be based on routinely scheduled visits during a 12-month follow up period for each participant up to a final follow-up when the participant discontinues treatment or at the end of follow-up period for any participants still taking lubiprostone. NOTE: This product was divested from Takeda to Jeil in 2022.
Interventions
OTHERNo Intervention
This is a non-interventional study.
Sponsors
Jeil Pharmaceutical Co., Ltd.
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. South Korean adult. 2. With constipation caused by: * Chronic Idiopathic Constipation (CIC), or * Opioid-Induced Constipation (OIC) from treatment for chronic, non-cancer pain, including participants with chronic pain related to prior cancer or its treatment who do not require frequent (example weekly) opioid dosage escalation. 3. Is newly prescribed (first incident) and initiates lubiprostone for the treatment of constipation.
Exclusion criteria
1. Treated with lubiprostone outside of the locally approved label in South Korea. 2. Participating in any other clinical study investigating one (or more) of the approved indications of lubiprostone.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Reporting One or More Adverse Events (AEs) | Up to 12 months | AEs is defined as any undesirable and unintended signs (example, abnormal laboratory values), symptoms, or diseases which occur during or following the administration of the drug, this does not necessarily require causal relationship. |
| Number of Participants Reporting One or More Serious Adverse Events (SAEs) | Up to 12 months | A SAE is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in the Frequency of Spontaneous Bowel Movement (SBM) at End of Treatment | Baseline up to end of treatment (approximately 12 months) | SBM is a bowel movement occurring in the absence of laxative use. Change from baseline values will be reported for participants who discontinue lubiprostone during study period. |
| Time to Resolution of Symptoms After Treatment Discontinuation | Up to 12 months | Time to resolution of symptoms defined as discontinuation of treatment with lubiprostone. |
| Change From Baseline in Frequency of SBM After 12-month Follow up | Up to 12 months | SBM is a bowel movement occurring in the absence of laxative use. Change from baseline values after 12-months follow up period will be reported for participants. |
Countries
South Korea
Contacts
Primary ContactYun Jeong Lim, M.D Ph.D
Outcome results
None listed